25.97
25.97 (0%)
As of Apr 17, 2025
Kymera Therapeutics, Inc. [KYMR]
Source:
Company Overview
Kymera Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of innovative, highly differentiated medicines that address significant health problems and that meaningfully improve patients’ lives.
| Country | United States |
| Headquarters | watertown, massachusetts |
| Phone Number | 857-285-5314 |
| Industry | |
| CEO | Nello Mainolfi |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $47.1 |
| Operating Profit | $-261.6 |
| Net Income | $-223.9 |
| Net Cash | $10.3 |
Profit Ratios
| Gross Margin | $47.1 |
| Operating Margin | -555.8 |
| Profit as % of Revenues | -21% |
| Profit as % of Assets | -28.8% |
| Profit as % of Stockholder Equity | -26.8% |
Management Effectiveness
| Return on Equity | -26.8% |
| Return on Assets | -22.9% |
| Turnover Ratio | 6.1% |
| EBITA | $-261.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $978 |
| Total Liabilities | $142.4 |
| Operating Cash Flow | $-194.5 |
| Investing Cash Flow | $-404.1 |
| Financing Cash Flow | $608.9 |
